English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16564/18988 (87%)
Visitors : 5423141      Online Users : 81
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/27773


    標題: An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA
    作者: Yen, M-C
    Weng, T-Y
    Chen, Y-L
    Lin, C-C
    Chen, C-Y
    Wang, C-Y
    Chao, H-L
    Chen, C-S
    Lai, M-D
    貢獻者: 老人服務事業管理系
    關鍵字: H1 Promoter
    Ido Shrna
    Indoleamine 2,3-Dioxygenase
    Osu-Hdac42
    Rna Polymerase Iii
    U6 Promoter
    日期: 2013-06
    上傳時間: 2014-05-26 10:43:05 (UTC+8)
    出版者: Nature Publishing Group
    摘要: Histone deacetylase (HDAC) inhibitors are used in treating certain human malignancies. Our laboratories demonstrated their capability in enhancing antitumor effect of DNA vaccine driven by an RNA polymerase II (RNA pol II) promoter. However, it is unknown whether HDAC inhibitors enhance the therapeutic short hairpin RNA (shRNA) expressed by an RNA polymerase III (RNA pol III) promoter. We investigated whether HDAC inhibitors augmented antitumor effect of indoleamine 2,3 dioxygenase (IDO) shRNA. HDAC inhibitor OSU-HDAC42 and suberoylanilide hydroxamic acid enhanced RNA pol III-driven U6 and H1 promoter activity in three different cell types in vitro: 293, NIH3T3 and dendritic cell line DC2.4. Subcutaneous injection of OSU-HDAC42 enhanced U6 and H1 promoter activity on abdominal skin of mice in vivo. Combination of IDO shRNA and OSU-HDAC42 increased antitumor effect of IDO shRNA in MBT-2 murine bladder tumor model. IDO shRNA induced tumor-infiltrating CD8(+) and CD4(+) T cells, whereas OSU-HDAC42 treatment induced tumor-infiltrating CD4(+) T cells. Combination of OSU-HDAC42 and IDO shRNA further induced tumor-infiltrating natural killer cells and enhanced interferon-gamma in lymphocytes, but suppressed interleukin (IL)-4 expression of lymphocytes. In addition, OSU-HDAC42 treatment did not alter mRNA expression of IL-12 and tumor necrosis factor-alpha. In conclusion, HDAC inhibitor OSU-HDAC42 may serve as adjuvant of the therapeutic shRNA expressed by an RNA pol III promoter.
    關聯: Cancer Gene therapy, v.20 n.6, pp.351-357
    Appears in Collections:[老人服務事業管理系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML639View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback